SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending as investors are keenly focused on recent technical breakouts and the potential for S&P 500 inclusion, with many anticipating a pre-earnings rally. The community is actively debating the impact of recent capital raises and the upcoming stablecoin launch, alongside performance targets for the CEO. Bullish sentiment is countered by concerns over past share dilution and price volatility, though the broader fintech sector's momentum adds to the conversation.

Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA.

Alumis Inc.

Alumis Inc. is trending sharply upward following positive Phase 3 clinical trial results for its oral TYK2 inhibitor, envudeucitinib, in moderate-to-severe plaque psoriasis, showcasing exceptional skin clearance rates. The community is actively debating if these strong efficacy outcomes justify the significant market reaction, with some anticipating a classic biotech pump-and-dump while others view it as a high-potential long-term opportunity in the competitive immunology space.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is trending due to its strategic collaboration with OpenAI, enhancing its Athena AI marketing platform with advanced conversational intelligence, an announcement made at CES 2026. This news has ignited strong community discussion, with many anticipating a significant short squeeze given the stock's high short interest and perceived undervaluation. Investors are actively highlighting Zeta's position as a burgeoning leader in the AI-driven MarTech sector and its strengthening fundamentals.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending due to overwhelming short squeeze speculation, fueled by exorbitant borrow fees, limited share availability, and its inclusion on the Reg SHO list. The community is actively celebrating the stock sustaining above the critical $5 mark, which is seen as a gateway for institutional investment, and expressing high conviction in the groundbreaking potential of its GPS immunotherapy for AML. This confluence of factors, including promising clinical trial progress suggesting significantly extended patient survival, is driving intense discussion around a potential multi-billion dollar buyout and a significant re-rating of the company's value.

Memecoin on Injective taken over by the community.

Nonja

NONJA is trending as a top meme coin on the Injective blockchain, driven by its strong community actively discussing its leveraged performance against INJ and resilience during market downturns. The community highlights NONJA's organic growth, high burned liquidity, and successful NFT collections, positioning it for significant gains as Injective's ecosystem benefits from its robust fundamentals and upcoming ETF considerations.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is currently experiencing a significant surge in trading volume, driving strong bullish sentiment and community discussions predicting a notable price ascent. The conversation highlights its foundational technology in IoT and decentralized data, bolstered by Japanese regulatory compliance and anticipated 2026 ecosystem developments, with many viewing it as a long-term investment in a real technology project.

Aeva Technologies, Inc. develops sensing paradigm for autonomous vehicles and robotics. The firm offers drones, robotics, vehicle technology, and virtual and augmented reality products. The company was founded by Soroush Salehian Dardashti and Mina Rezk in 2017 and is headquartered in Mountain View, CA.

Aeva Technologies Inc

Aeva Technologies is generating significant buzz following announcements at CES 2026, most notably the integration of its 4D LiDAR as a reference sensor within the NVIDIA DRIVE Hyperion Platform ecosystem. The community is highly enthusiastic about this validation and Aeva's new Omni sensor for Physical AI applications, anticipating substantial stock appreciation driven by its low float and perceived technological leadership.

Bright Minds Biosciences, Inc. is a biotechnology company, which engages in the development of therapeutics. The company was founded by Ian B. McDonald and Alan P. Kozikowski on May 31, 2019 and is headquartered in Chicago, IL.

Bright Minds Biosciences Inc

Bright Minds Biosciences is currently trending following positive Phase 2 clinical data for BMB-101, showing strong efficacy and a clean safety profile in treating drug-resistant epilepsy. This promising update has ignited intense community discussion, with many drawing parallels to prior explosive biotech surges and debating the potential for a significant short squeeze, while others express surprise at the market's reaction despite the scientific advancements.

Terrestrial Energy, Inc. is an advanced nuclear technology company focused on next-generation nuclear energy systems. The company is developing the Integral Molten Salt Reactor (IMSR), an innovative type of Generation IV molten salt reactor designed to produce reliable, low-carbon heat and electricity at competitive costs. The company is headquartered in Charlotte, NC.

Terrestrial Energy Inc.

Terrestrial Energy (IMSR) is trending due to its pivotal role in the U.S. Department of Energy's Advanced Reactor Pilot Program, targeting an Integral Molten Salt Reactor pilot by July 2026, complemented by a recent Westinghouse contract for advanced nuclear fuel. The community is actively debating its significant undervaluation compared to peers like OKLO, highlighting its LEU fuel advantage and potential to power future AI data centers and industrial heat. Despite recent post-SPAC volatility, many investors view current levels as a key accumulation opportunity for this government-backed nuclear innovator.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo Inc. is trending as investors eagerly await a U.S. Department of Energy announcement on surplus plutonium fuel allocation, seen as critical for its advanced reactor development and the broader 'American Energy Dominance' push. The community is actively discussing the potential for 'fast-track' licensing for Small Modular Reactors and a significant short squeeze, driven by expectations that Oklo is poised to power the growing energy demands of AI data centers.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Best-Performing Active ETFs of 2025

Active ETFs shined in 2025 as GBUG, WGMI, PSIL, MKOR & LFSC delivered outsized gains amid gold, crypto and niche themes.

<ul class="summary-bullets"><li>With an estimated 51.5 million U.S. adults suffering from mental illness and the psychedelic drug market projected to grow at a 15% CAGR to nearly $13 billion by 2035</li><li>&nbsp;Both Compass Pathways and Mind Medicine are positioned to tap a massive unmet need.</li><li>Mind Medicine leads in retail sentiment, cash runway into 2028, and late-stage progress with MM120, while Compass Pathways’ COMP360 could reach the market sooner.</li></ul>After years on the fringes of mainstream medicine, psychedelic drugmakers are suddenly finding themselves in the spotlight.Shares of companies developing psychedelic-based therapies surged this year, buoyed by a gradual softening of regulatory resistance, growing political support, and a string of company-specific catalysts. Positive clinical trial readouts, renewed investor appetite, and a pickup in merger-and-acquisition chatter have all helped fuel momentum across the space.As optimism builds around the therapeutic potential of psychedelics to treat conditions ranging from depression to PTSD, two names have stood out among the pack: Compass Pathways and Mind Medicine. Here’s a closer look at how these two psychedelic high-fliers compare — and what’s driving their rise.<h2 class="st-heading-2">Psychedelics Turn Mainstream</h2>Stymied by regulatory roadblocks, research into hallucinogenic compounds remained largely dormant for decades. However, a gradual regulatory thaw and a growing mental-health crisis have sparked renewed scientific interest. Psychedelics such as psilocybin, MDMA, and LSD are moving into the mainstream of psychological research, backed by robust clinical trials and growing institutional support.&nbsp;The psychedelics drug market is expected to grow at a compounded annual growth rate (CAGR) of 15% to nearly $13 billion in 2035 from $3 billion in 2025,&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.rootsanalysis.com/reports/global-psychedelic-therapeutics-market.html">according</a> to Business Research and Consulting Group Roots Analysis.<img src="https://news.stocktwits-cdn.com/Psychedelics_Market_png_7463be0aca.webp" alt="Psychedelics Market.png">Source: Roots AnalysisThe&nbsp;<a href="https://stocktwits.com/symbol/PSIL">AdvisorShares Psychedelics ETF (PSIL)</a> has outperformed the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, which tracks the broader S&amp;P 500 Index.<img src="https://news.stocktwits-cdn.com/PSIL_Vs_SPY_png_168a676f0b.webp" alt="PSIL Vs SPY.png">Source: Koyfin<h2 class="st-heading-2">What Has Turned The Tide?</h2>This class of drugs has received strong backing from high-profile personalities, including Health Secretary Robert F. Kennedy Jr. and FDA Commissioner Dr. Martin Makary. Kennedy has previously&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/mnmd-stock-soars-after-rfk-jr-confirmed-as-hhs-chief/ch5iJvpRH6">advocated</a> for decriminalizing psychedelics for therapeutic use, citing his son’s positive experience with the hallucinogenic brew ayahuasca.As an extension, the FDA has accorded top priority to review MDMA and other psychedelics, even mulling accelerated approval for these drugs.&nbsp;Big pharma name AbbVie announced an agreement to acquire Gilgamesh Pharmaceuticals' novel psychedelic therapy candidate, bretisilocin, in August for up to $1.2 billion, lending credence to this class of medication. Atai, a biotech developing treatments for mental health, merged with Beckley Psytech, bringing Beckley's BPL-003, an investigational therapy for treatment-resistant depression (TRD) and alcohol use disorder (AUD), into its pipeline. ATAI Beckley’s stock has gained 220% this year.<h2 class="st-heading-2">Compass Pathways Vs. Mind Medicine</h2>Mind Medicine stock has returned about 110% year-to-date, compared with the 84% gain for Mind Medicine.<img src="https://news.stocktwits-cdn.com/MNMD_Vs_CMPS_png_35ac2a510a.webp" alt="MNMD Vs CMPS.png">Source: KoyfinThe primary draw for these stocks lies in the sheer size of the market opportunity. In a presentation, Mind Medicine highlighted that roughly 51.5 million adults in the U.S. are affected by mental illness, underscoring the vast and largely underserved demand for effective treatments.Mind Medicines’ lead candidate MM120 orally disintegrating tablet (ODT) is in late-stage trials for major depressive disorder (MDD). Topline data from the study is due in mid-2026. Delving into the upcoming catalysts, CEO Rob Barrow said in the third-quarter earnings release:<blockquote>“We plan to initiate Ascend, our second Phase 3 study in MDD, in mid-2026 and remain focused on advancing toward FDA submissions in both generalized anxiety disorder (GAD) and major depressive disorder (MDD). With multiple anticipated Phase 3 topline data readouts ahead, 2026 is set to be the most significant year in our history to date. ”</blockquote>Mind Medicine reported no revenue and a net loss of $67.3&nbsp;million for the three months ended Sept. 30, 2025. On the other hand, Compass Pathways’ net loss stood at $137.72 million for the September quarter,&nbsp;compared with a loss of $38.50 million a year&nbsp;earlier.London-based Compass Pathways’ lead candidate COMP360, a synthetic formulation of psilocybin that is in late-stage clinical trials for treating mental health conditions, primarily treatment-resistant depression (TRD). CEO Kabir Nath said in the earnings release that the company was moving up the expected launch timing for COMP360 in TRD by 9 to 12 months. The company&nbsp;intends to file for approval by the second half of 2026.&nbsp;<h2 class="st-heading-2">MNMD Vs. CMPS: Cash Position</h2>Mind Medicine has beefed up its cash position with a recent offering. It said its cash, cash equivalents, and investments as of September 30, 2025 ($209.1 million), along with the net proceeds of $242.8 million from the recently completed offering, will be sufficient to fund the operations into 2028. Meanwhile, Compass Pathways had a smaller cash reserve at a comparable point, but the company said it would be enough to fund operating expenses and capital expenditures through 2027.<img src="https://news.stocktwits-cdn.com/Cash_Position_Sufficient_For_Medium_Term_png_e0ea50d775.webp" alt="Cash_Position_Sufficient_For_Medium_Term.png">Source: Fiscal.ai<h2 class="st-heading-2">MNMD Vs. CMPS: How Retail’s Positioned</h2>Retail traders, however, are favorably disposed to Mind Medicine. On Stocktwits, retail sentiment toward the stock has been ‘bullish’ as of early Wednesday.<figure class="image"><img style="aspect-ratio:712/439;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_24_at_8_37_12_AM_png_3de00ad9f2.webp" alt="Screenshot 2025-12-24 at 8.37.12 AM.png" width="712" height="439"></figure>Compass Pathways, meanwhile, attracted ‘neutral’ sentiment among retailers, with sentiment showing volatility throughout the year.<figure class="image"><img style="aspect-ratio:721/436;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_24_at_8_39_54_AM_png_d4c6176ec9.webp" alt="Screenshot 2025-12-24 at 8.39.54 AM.png" width="721" height="436"></figure>According to Koyfin, the average analyst price target for Mind Medicine stock is $28.67, implying 105% upside potential. All 13 analysts covering the stock have either a ‘Buy’ or a ‘Strong Buy’ rating on the stock. Compass Pathways stock, meanwhile,&nbsp;has 144% upside potential, based on the average price target of $16.82. All but one of the 11 analyst covering the stock has bullish ratings.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-revamps-robotaxi-website-revamp-how-competition-stacks-up/cLesMvuREv3">Tesla Signals Robotaxi Expansion With Website Revamp — Here’s How The Competition Stacks Up</a>

 Creative image of an Hallucinogenic mushroom. (Representative image courtesy of Aitor Diago via Getty Images)

Psychedelics Break Out Of The Fringe Under RFK Jr’s 2025 Reset — But Did MNMD Or CMPS Own The Year?

Regulatory thaw, political backing, and late-stage data are propelling psychedelic drugmakers into the biotech spotlight — with Compass Pathways and Mind Medicine leading the charge.

Equity

Regulatory thaw, political backing, and late-stage data are propelling psychedelic drugmakers into the biotech spotlight — with Compass Pathways and Mind Medicine leading the charge.


<ul class="summary-bullets"><li>The analyst noted that sponsors must continue producing study data to suggest psychedelics can safely produce profound efficacy in mental health.</li><li>Jefferies added that it believes Atai Beckley's (ATAI) proprietary psychedelics have promise.</li><li>The AdvisorShares Psychedelics ETF (PSIL), which invests in the emerging psychedelic drugs sector, traded 1.3% higher at the time of writing.</li></ul>Jefferies analyst Andrew Tsai now sees positive tailwinds forming for non-recreational psychedelics after President Trump signed an executive order on Thursday directing his administration to reclassify marijuana.The firm now sees non-recreational psychedelics eventually follow suit, as long as sponsors continue producing study data to suggest psychedelics can safely produce profound efficacy in mental health. This, the analyst believes, is arguably a function of time.&nbsp;Jefferies added that it believes pharmaceutical company Atai Beckley's (<a href="https://stocktwits.com/symbol/ATAI">ATAI</a>) proprietary psychedelics have promise. AtaiBeckley’s pipeline includes investigational therapies for treatment-resistant depression and social anxiety disorder.Shares of psychedelics-related stocks rallied on Friday. While ATAI stock traded 0.4% higher at the time of writing, Supernus (<a href="https://stocktwits.com/symbol/SUPN">SUPN</a>) and Cybin (<a href="https://stocktwits.com/symbol/CYBN">CYBN</a>) shares rose about 5%.The AdvisorShares Psychedelics ETF (<a href="https://stocktwits.com/symbol/PSIL">PSIL</a>), which invests in the emerging psychedelic drugs sector, also traded 1.3% higher.<h2 class="st-heading-2">Trump Cannabis Order</h2>President Donald Trump on Thursday <a href="https://stocktwits.com/news-articles/markets/equity/tilray-canopy-growth-stock-rise-as-trump-signs-executive-order-to-lower-marijuana-restrictions/cLegUFuREr0">signed</a> an executive order to reschedule marijuana to make it less restrictive and available for “legitimate medical uses.” Trump is seeking to move marijuana from a schedule 1 drug to a schedule 3 drug, from the levels of heroin, down to the levels of tylenol.Trump clarified that the order is not federal legalization and does not allow for recreational use nationwide but is instead aimed at improving medical marijuana and cannabidiol research. The Centers for Medicare &amp; Medicaid Services (CMS) is also working on a plan to test making some Medicare patients eligible for therapies derived from cannabinoids or compounds derived from the Cannabis plant.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around PSIL fell from ‘neutral’ to ‘bearish’ territory over the past 24 hours, while sentiment around ATAI also took a dip to ‘extremely bearish’ levels.Sentiment around SUPN stayed ‘neutral,’ while sentiment around CYBN stayed ‘extremely bullish’.A Stocktwits user highlighted a positive study from 2022 on Psilocybin, a naturally occurring psychedelic compound, in treating depression symptoms.<stembedurl>https://www.stocktwits.com/DJS777/message/639663641</stembedurl>As per the study published in the New England Journal of Medicine, participants reported a greater reduction in levels of depression three weeks after taking a 25 mg dose of psilocybin, compared to those who took the lowest 1 mg dose.PSIL has gained 68% this year and by 76% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/cassava-sciences-stock-on-track-for-worst-day-in-about-9-months/cLe0RFtREsu">Cassava Sciences Stock On Track For Worst Day In About 9 Months — What’s Driving Today’s Selloff?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Digitally generated image of brain filled with multicolored particles. | Source: Getty Images

Optimism Flows From Pot To Psychedelics: Atai Beckley, Supernus Stocks Rise After Analyst Flags Positive Tailwinds From Trump’s Marijuana Order

Jefferies sees restrictions around non-recreational psychedelics eventually loosen up.  

<ul class="summary-bullets"><li>The company expects gross proceeds of about $60 million from the offering, which it intends to use for general corporate purposes.</li><li>Pasithea expects the offering to close on or about December 1.</li></ul>Pasithea Therapeutics Corp. (KTTA) on Friday announced the pricing of a public offering of 80 million shares of the company’s common stock at $0.75 per share.KTTA shares traded 43% higher on Friday morning at the time of writing.<h2 class="st-heading-2">Offering Proceeds And Purpose</h2>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/28/3196323/0/en/Pasithea-Therapeutics-Announces-Pricing-of-60-Million-Public-Offering-of-Common-Stock.html">expects</a> gross proceeds of about $60 million from the offering, which it intends to use for general corporate purposes such as ongoing research and pre-clinical studies, clinical trials, the development of new biological and pharmaceutical technologies, and investing in or acquiring companies that are synergistic with or complementary to the company’s technologies, among others.The offer price represents a 29% discount to the stock’s Wednesday closing price.The company said that it expects the offering, led by investors including Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle Investments, Adage Capital Partners, and Squadron Capital Management, to close on or about December 1. The offering will extend its cash runway through at least the first half of 2028, it added. &nbsp;Earlier this month, the company was awarded a Hoffman ALS Clinical Trial Award grant worth about $1 million to study its lead drug candidate, PAS-004, in Amyotrophic lateral sclerosis (ALS) patients. ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord, where patients eventually lose the ability to breathe.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/KTTA">KTTA stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.A Stocktwits user opined that the stock will erode its gains to hit $0.75 level.<stembedurl>https://stocktwits.com/GABBYGIRL/message/637652497</stembedurl>KTTA stock is down by 52% this year.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/china-byd-recalls-nearly-89000-evs/cL5aGIxRELP">China’s BYD Recalls Nearly 89,000 EVs – Regulator Cites Battery Output Concerns</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

Why Did KTTA Stock Soar A Whopping 43% Today?

The company announced the pricing of a public offering of 80 million shares of its common stock and said that the offering will extend its cash runway through at least the first half of 2028.

<ul class="summary-bullets"><li>The strategic review comes after Neuphoria discontinued advancing its lead drug candidate called BNC210 for the treatment of social anxiety disorder in October.</li><li>Strategic alternatives under consideration may include, but are not limited to, mergers, acquisitions, partnerships, joint ventures, licensing arrangements, or other strategic transactions, the company said.</li><li>The company said it will carefully evaluate and consider Lynx1 Master Fund’s indication of interest in connection with its review of strategic alternatives.</li></ul> Neuphoria Therapeutics Inc. (NEUP) initiated a review of strategic alternatives, including potential acquisitions, on Tuesday to advance its pipeline programs and maximize shareholder value.NEUP shares traded 4% higher in the pre-market session at the time of writing.<h2 class="st-heading-2">Strategic Alternatives Under Consideration</h2>Strategic alternatives under consideration may include, but are not limited to, mergers, acquisitions, partnerships, joint ventures, licensing arrangements, or other strategic transactions, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.neuphoriatx.com/news-releases/news-release-details/neuphoria-announces-initiation-strategic-review-maximize">said.</a>The company added that it does not have a defined timeline for exploring strategic alternatives. Further, it is not confirmed that the process will result in a transaction.The strategic review comes after Neuphoria discontinued advancing its lead drug candidate called BNC210 for the treatment of social anxiety disorder in October after a late-stage trial missed its primary and secondary endpoints. Neuphoria then also said it will assess new development paths for BNC210 as a treatment for post-traumatic stress disorder (PTSD).<h2 class="st-heading-2">Lynx1 Master Fund Expresses Interest</h2>Neuphoria on Tuesday also added that it received an unsolicited non-binding indication of interest from Lynx1 Master Fund LP earlier this week to acquire all of the outstanding shares of Neuphoria that it does not already own for $5.20 per share in cash. The company said it will carefully evaluate and consider this indication of interest in connection with its review of strategic alternatives.Lynx1 Master Fund LP also expressed intent to nominate certain individuals to stand for election to Neuphoria’s Board of Directors at the company’s 2025 Annual Meeting of Stockholders, the company said. Neuphoria’s Board of Directors will now review the proposed director nominees. The annual meeting is scheduled for December 12.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NEUP">NEUP stock</a> jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.<figure class="image"><img style="aspect-ratio:623/62;" src="data:image/png;base64,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" width="623" height="62" alt="NEUP's Sentiment Meter and Message Volume as of 8:28 a.m. ET on Nov. 11, 2025 | Source: Stocktwits"><figcaption>NEUP's Sentiment Meter and Message Volume as of 8:28 a.m. ET on Nov. 11, 2025 | Source: Stocktwits</figcaption></figure>NEUP stock is up by 43% this year and by 11% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/poet-technologies-and-quantum-computing-team-up-to-boost-ai-data-speeds/cLPdoHVREPl">POET Technologies And Quantum Computing Team Up To Boost AI Data Speeds</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Global stock market chart and trading board - stock photo

NEUP Shares Rise Pre-Market As It Explores Strategic Alternatives, Including Potential Acquisition

Neuphoria also added that it received an unsolicited non-binding indication of interest from Lynx1 Master Fund LP earlier this week to acquire all of the outstanding shares of Neuphoria that it does not already own for $5.20 per share in cash. 

Shares of Compass Pathways Plc. (CMPS) slumped 47% on Monday afternoon after the <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.compasspathways.com/News--Events-/news/news-details/2025/Compass-Pathways-Successfully-Achieves-Primary-Endpoint-in-First-Phase-3-Trial-Evaluating-COMP360-Psilocybin-for-Treatment-Resistant-Depression/default.aspx">results</a> from the late-stage trials of COMP360 in treatment-resistant depression fell short of market expectations.COMP360 is a synthetic, proprietary formulation of psilocybin. Psilocybin is part of a group of drugs called psychedelics or hallucinogens with the ability to alter one’s sense of perception.Compass Pathways said that a single dose of the drug reduced symptom severity by 3.6 points from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) as compared to placebo at week 6.The company said it will discuss the “highly statistically significant and clinically meaningful” data with the U.S. Food and Drug Administration, which has yet to review it.The company is also running another late-stage trial for the drug, which aims to evaluate the efficacy of two fixed doses taken three weeks apart.According to Compass Pathways, an estimated 21 million adults in the U.S. suffer from major depression, and approximately 9 million are drug-treated.Approximately a third of patients with major depressive disorder will develop treatment-resistant depression, which is defined as an inadequate response to two or more appropriate courses of approved medications.Following the announcement, Evercore ISI downgraded Compass Pathways to ‘In Line’ from ‘Outperform’ with a price target of $6, down from $11.The reduction in symptom severity by 3.6 points as compared to placebo on a standardized depression scale "underwhelmed," the analyst told investors, as per TheFly.This dataset does indicate Compass may have an approvable drug, but the firm noted that durability is a key component for commercial success, and this will remain a question with relatively unclear durability in a mid-stage trial and a weaker effect at 6 weeks in the late-stage trial.H.C. Wainright, however, is more optimistic and noted that the results from the late-stage study mark "a historic first for a psychedelic therapy." The data also positions COMP360 as "a potential first-in-class treatment in a large, underserved depression market," said the analyst, who reiterated a ‘Buy’ rating and $45 price target on the shares.On Stocktwits, retail sentiment around CMPS jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:631/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_23_at_12_27_47_PM_png_d7e1356560.webp" alt="CMPS's Sentiment Meter and Message Volume as of 12:25 p.m. ET on June 23, 2025 | Source: Stocktwits" width="631" height="60"><figcaption>CMPS's Sentiment Meter and Message Volume as of 12:25 p.m. ET on June 23, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that while the late-stage results were good, the market wants ‘groundbreaking’ results.<stembedurl>https://stocktwits.com/aaronmag13/message/618680560</stembedurl><a href="https://stocktwits.com/symbol/CMPS">CMPS stock</a> is down by about 35% this year and nearly 61% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/rezolve-ai-to-be-added-to-russell-indices-after-revenue-surge/chm57C7RRdR">Rezolve Ai To Be Added To Russell Indices After Revenue Surge: Retail Echoes Confidence</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Compass Pathways Stock Slumps After Positive Late-Stage Trial Results From Psychedelic Drug ‘Underwhelm’ Analysts

The company said it will discuss the “highly statistically significant and clinically meaningful” data with the U.S. Food and Drug Administration, which has yet to review it.

5 ETFs That Beat the Market in the First Half of 2025

Shares of NRx Pharmaceuticals Inc. surged nearly 25% on Tuesday, its best session in&nbsp;almost three weeks, drawing heavy interest from retail traders.The surge followed news of a $27 million funding deal to fund the company’s planned purchase of Hope clinics.NRx’s Hope Therapeutics unit announced a stock purchase agreement with Smith &amp; Sauer, a private investment firm specializing in healthcare and technology investments.&nbsp;The agreement includes an immediate $2 million investment in NRx common stock and a $25 million purchase of Hope’s Series A preferred shares, with $6.75 million due by Feb. 7 and the remainder by April 1.&nbsp;The funds will be used to expand Interventional Psychiatry Clinics focused on treating severe depression and other psychological disorders.Chairman Jonathan Javitt said the resources committed are expected to bring NRx to the $100 million revenue threshold.&nbsp;He added that the company had initiated a financial advisory relationship to raise an additional $400 million for broader expansion.&nbsp;"Psychedelic Medications such as ketamine, neuromodulation technologies such as TMS, and digital therapeutics have sparked a revolution in psychiatry where for the first time patients with life threatening conditions such as depression and PTSD hope for a brighter future,” he said.Retail traders on Stocktwits took note, with message volume surging 94% on Tuesday and remaining at high levels ahead of Wednesday’s market open.&nbsp;Sentiment on the stock turned ‘bullish,’ with investors speculating on the impact of the projected $100 million revenue on earnings and share price.&nbsp;One user even predicted that the stock could more than double from current levels.<stembedurl>https://stocktwits.com/jonny80s/message/601877421</stembedurl><stembedurl>https://stocktwits.com/TheRealBomb/message/601781798</stembedurl>Despite losing 11% in value over the past year, NRx Pharmaceuticals has seen a 177% gain in the past three months, driven by increasing retail interest.&nbsp;The company’s follower count on Stocktwits has risen 3% over the last 12 months, while message volume has jumped 188%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

Small-Cap NRx Pharma’s Stock Draws Heavy Retail Buzz After Securing $27M Funding 

Chairman Jonathan Javitt said the resources committed are expected to bring NRx to the $100 million revenue threshold. 

Shares of Mind Medicine Inc. climbed over 2% on Tuesday afternoon, on track to break a two-session losing streak, as Evercore ISI initiated coverage with an&nbsp;‘Outperform’&nbsp;rating and a bullish $23 price target, suggesting over 200% upside from current levels.Evercore analysts highlighted the company’s innovation in developing a novel oral formulation of LSD, with its lead asset MM120 targeting generalized anxiety disorder (GAD) and major depressive disorder (MDD).&nbsp;The brokerage also pointed to potential large-scale expansion opportunities and emphasized the growing acceptance of psychedelics in future treatment paradigms.Last month, Chardan initiated coverage with a&nbsp;‘Buy’ rating and a $20 price target, citing MM120’s potential to deliver over $1 billion in peak sales by 2026, assuming positive trial data and a strong commercial launch.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/MNMD_sentiment_and_message_volume_Jan_28_9a6374b37a.png" alt="MNMD sentiment and message volume Jan 28.png" width="1318" height="324"><figcaption>MNMD sentiment and message volume Jan 28 as of 12:45 pm ET | source: Stocktwits</figcaption></figure>On Stocktwits, retail sentiment for Mind Medicine turned ‘bullish’ from ‘neutral,’ with increased message volume reflecting optimism.&nbsp;<stembedurl>https://stocktwits.com/EMT6/message/601825856</stembedurl><stembedurl>https://stocktwits.com/MichaelNaussCMT/message/601770767</stembedurl>Analysts expect sentiment to improve further in 2025, as the company nears key catalysts, including pivotal trial updates.Mind Medicine recently launched a Phase 3 trial of MM120 in GAD and expanded its intellectual property protection through 2041 by obtaining a patent for an orally disintegrating tablet (ODT) formulation.&nbsp;The Nasdaq Biotechnology Index (NBI) added the stock in December, which analysts noted could bolster institutional interest.The company ended the third quarter of 2024 with $295.28 million in cash and $24.31 million in debt.&nbsp;<a href="https://stocktwits.com/symbol/MNMD">Mind Medicine</a> recently said it raised $250 million last year through two equity financings.The small-cap biotech’s stock has returned about 90% over the past 12 months, though its short interest stands at 13.6%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

The company’s lead asset MM120 targets generalized anxiety disorder (GAD) and major depressive disorder (MDD). | Image source: Getty Images

Mind Medicine Stock Rises As Evercore Projects 200% Upside On LSD Formulation: Retail Turns Bullish

The brokerage also pointed to potential large-scale expansion opportunities and emphasized the growing acceptance of psychedelics in future treatment paradigms. 

Shares of Cybin, Inc. (<a class="mention" data-mention="$CYBN" data-symbol-id="CYBN" href="https://stocktwits.com/symbol/CYBN" target="_blank">$CYBN</a>) surged as much as 10% on Monday, reaching their highest level since May, following the announcement of “unprecedented” 12-month efficacy data from a Phase 2 study of the biopharma’s major depressive disorder (MDD) treatment.The company reported that two 16 mg doses of CYB003, a proprietary deuterated psilocin program, spaced three weeks apart, showed “consistent, robust, and sustained” treatment benefits through the 12-month follow-up.&nbsp;This data supports the potential of CYB003 as an adjunctive treatment for MDD patients who have not achieved remission with first-line antidepressants, Cybin said.The U.S. Food and Drug Administration (FDA) recently granted CYB003 Breakthrough Therapy Designation, accelerating its review process.Cybin’s CEO, Doug Drysdale, noted that the results validate the company’s approach and could revolutionize the standard of care in MDD treatment.&nbsp;“We are quite possibly witnessing a watershed moment in mental health care treatment paradigms and practices,” he said.Drysdale emphasized that current treatments, such as esketamine and electroconvulsive therapy (ECT), require up to 36 outpatient visits per treatment cycle, creating a significant burden on both patients and healthcare facilities.&nbsp;In contrast, CYB003’s two-dose treatment regimen could offer a more patient-friendly, long-lasting alternative.On Stocktwits, retail sentiment for CYBN turned ‘extremely bullish,’ with users expressing optimism about the future of the company and its potential impact on mental health care.&nbsp;Some users pointed to potential regulatory support under a Trump administration, suggesting that prominent figures like Robert F. Kennedy Jr. as HHS Secretary could expedite FDA approval for CYB003.<stembedurl>https://stocktwits.com/PsychedStocks/message/592985335</stembedurl>Another hoped that the stock would double to $25 soon.&nbsp;<stembedurl>https://stocktwits.com/DJTHollaAtMe/message/593002464</stembedurl>Analyst firms remain optimistic, even as Canaccord maintained a ‘Buy’ rating while lowering its price target to $86 from $96 last week.&nbsp;Alliance Global Partners, meanwhile, raised its target to $25 from $6, reflecting the potential upside based on CYB003’s progress and ongoing Phase 3 trials.Still, Cybin’s stock has seen a 19% decline year-to-date.&nbsp;For updates and corrections, email newsroom@stocktwits.comRead next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lbrt-stock-rises-as-ceo-to-join-trump-cabinet/cJ4vdwSRQe">Liberty Energy Stock Pops Following CEO’s Nomination To Trump’s Cabinet: Retail Buzz Grows</a>

The U.S. Food and Drug Administration (FDA) recently granted Cybin's CYB003 Breakthrough Therapy Designation, accelerating its review process.

Cybin Stock In Focus On MDD Treatment's 'Breakthrough’ Efficacy: Retail Turns Extremely Bullish

Cybin's CEO, Doug Drysdale, noted that the results validate the company’s approach and could revolutionize the standard of care in MDD treatment.

Cybin’s CEO, Doug Drysdale, noted that the results validate the company’s approach and could revolutionize the standard of care in MDD treatment.

Advisorshares Trust - AdvisorShares Psychedelics ETF

Physical AI Infrastructure

Power & Energy to Support Growth

Healthcare Value & Innovation

Other – Comment Below

As markets head into 2026, investors are debating whether the next phase favors speculation or real-world execution. With capital rotating toward infrastructure, energy, and undervalued sectors like healthcare, which area do you think will matter most for portfolios in the year ahead?

Which Theme Will Matter Most for Portfolios in 2026?

PSIL
AdvisorShares Psychedelics ETF

Feed

News

Sentiment

Fundamentals

Info

Latest PSIL News

PSILAdvisorShares Psychedelics ETF